Rifaximin therapy and clostridium difficile infection: A note of caution

Journal of Clinical Gastroenterology

Volumn 47, Issue 8, 2013, Pages 737-

  Zullo, Angelo ^a   Ridola, Lorenzo ^a   Hassan, Cesare ^a  

^a NUOVO REGINA MARGHERITA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAXIMIN;

ANTIBIOTIC THERAPY; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; CROHN DISEASE; HEPATIC ENCEPHALOPATHY; HUMAN; LETTER; LONG TERM CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ANTI-INFECTIVE AGENTS; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HEPATIC ENCEPHALOPATHY; HUMANS; MALE; RIFAMYCINS;

EID: 84883219186     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31828bea4b     Document Type: Letter

References (5)

1. Neff GW, Jones M, Jonas M, et al. Lack of Clostridium difficile infection in patients treated with rifaximin for hepatic encephalopathy. A retrospective analysis. J Clin Gastroenterol. 2013; 47: 188-192.
2. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362: 1071-1081.
3. Prantera C, Lochs H, Grimaldi M, et al. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology. 2012;142: 473-481.
4. Zullo A, Hassan C, Ridola L, et al. Rifaximin therapy and hepatic encephalopathy: pros and cons. World J Gastrointest Pharmacol Ther. 2012;3: 62-67.
5. Farrell DJ. Rifaximin in the treatment of irritable bowel syndrome: is there a high risk for development of antimicrobial resistance? J Clin Gastroenterol. 2013; 47: 205-211.